DnB Asset Management
CLDX icon

DnB Asset Management’s Celldex Therapeutics CLDX Stock Holding History

DnB Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$574K Buy
18,087
+1,186
+7% +$32.3K ﹤0.01% 725
2025
Q4 		$459K Buy
16,901
+3,650
+28% +$96.1K ﹤0.01% 681
2025
Q3 		$343K Buy
13,251
+951
+8% +$22K ﹤0.01% 688
2025
Q2 		$250K Sell
12,300
-334
-3% -$6.5K ﹤0.01% 681
2025
Q1 		$229K Buy
12,634
+2,503
+25% +$55.9K ﹤0.01% 703
2024
Q4 		$256K Sell
10,131
-38
-0.4% -$1.03K ﹤0.01% 698
2024
Q3 		$346K Buy
10,169
+2,297
+29% +$87.5K ﹤0.01% 675
2024
Q2 		$292K Buy
7,872
+2,523
+47% +$95.2K ﹤0.01% 675
2024
Q1 		$224K Buy
+5,349
New +$220K ﹤0.01% 692

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return